Related Experiment Video

Updated: Aug 9, 2026

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)
07:15

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)

Published on: July 3, 2025

Heart failure reduces both the effects and interaction between cyclic GMP and cyclic AMP

Jacob Moalem1, Harvey R Weiss, Tomer Davidov

  • 1Department of Surgery, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey, USA.

The Journal of Surgical Research
|March 21, 2006
PubMed

Insights

Cyclic AMP lessens cyclic GMP's negative effects in healthy hearts, but this protective interaction is diminished in heart hypertrophy and failure. This finding is crucial for understanding cardiac function in disease states.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Biochemistry

Background:

  • Cyclic guanosine monophosphate (cGMP) exerts negative functional effects on the heart.
  • Cyclic adenosine monophosphate (cAMP) is hypothesized to attenuate these cGMP effects.
  • This interaction may be impaired in pathological cardiac conditions like hypertrophy and failure.

Purpose of the Study:

  • To investigate the interaction between cyclic AMP and cyclic GMP in regulating cardiac function.
  • To determine if pacing-induced cardiac hypertrophy and failure alter this cAMP-cGMP interaction.
  • To assess the functional and metabolic consequences of these cyclic nucleotides in normal and failing hearts.

Main Methods:

  • Infusion of 8-bromo-cGMP and isoproterenol into the coronary arteries of control, hypertrophic (HYP), and hypertrophic failure (HYP-FAIL) dogs.
  • Measurement of regional myocardial work and oxygen consumption (VO(2)).
  • Determination of cyclic GMP and cyclic AMP levels via radioimmunoassay.

Main Results:

  • 8-bromo-cGMP decreased myocardial work and VO(2) in control dogs, but not in HYP or HYP-FAIL groups.
  • Isoproterenol increased work and VO(2) in control and HYP dogs, but decreased them in HYP-FAIL dogs.
  • Cyclic AMP levels were elevated by isoproterenol in control and HYP dogs, and further increased by 8-bromo-cGMP in controls, but not in HYP-FAIL dogs.

Conclusions:

  • Cyclic AMP attenuates the negative functional and metabolic effects of cyclic GMP in healthy hearts.
  • This protective interaction between cyclic AMP and cyclic GMP is significantly blunted in cardiac hypertrophy and failure.
  • The impaired interaction suggests a mechanism contributing to the functional decline in hypertrophic and failing hearts.
Abstract

More Related Videos

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System06:40

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System

Published on: May 22, 2018

Related Concept Videos

G-Protein Gated Ion Channels01:21

G-Protein Gated Ion Channels

GPCRs are primarily responsible for our sense of smell, taste, and vision.  The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory organs,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...